These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 35501725)

  • 1. High MICAL-L2 expression and its role in the prognosis of colon adenocarcinoma.
    Yang Y; Ye F; Xia T; Wang Q; Zhang Y; Du J
    BMC Cancer; 2022 May; 22(1):487. PubMed ID: 35501725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 4. High expression of NXPH4 correlates with poor prognosis, metabolic reprogramming, and immune infiltration in colon adenocarcinoma.
    Sun Z; Wang H; Xu Y; Liu Y; Wang L; Zhou R; Zhou R; Ma W; Zhang T
    J Gastrointest Oncol; 2024 Apr; 15(2):641-667. PubMed ID: 38756632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y
    Front Oncol; 2022; 12():876660. PubMed ID: 35747790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INSC Is Down-Regulated in Colon Cancer and Correlated to Immune Infiltration.
    Yu T; Li D; Zeng Z; Xu X; Zhang H; Wu J; Song W; Zhu H
    Front Genet; 2022; 13():821826. PubMed ID: 35664320
    [No Abstract]   [Full Text] [Related]  

  • 8. [High expression of ANKRD6 is an indicator for poor prognosis of colon adenocarcinoma].
    Zhao H; Liu G; Li Y; Yang N; Zhao J
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Oct; 43(10):1715-1724. PubMed ID: 37933647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of DLL3-related genes affecting the prognosis of patients with colon adenocarcinoma.
    Xiang J; Gong W; Liu J; Zhang H; Li M; Wang R; Lv Y; Sun P
    Front Genet; 2023; 14():1098190. PubMed ID: 37274780
    [No Abstract]   [Full Text] [Related]  

  • 10. Circadian Clock Genes Are Correlated with Prognosis and Immune Cell Infiltration in Colon Adenocarcinoma.
    He A; Huang Z; Zhang R; Lu H; Wang J; Cao J; Feng Q
    Comput Math Methods Med; 2022; 2022():1709918. PubMed ID: 35116071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification prognosis-associated immune genes in colon adenocarcinoma.
    Miao Y; Wang J; Ma X; Yang Y; Mi D
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33140821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a prognosis and chemotherapy evaluating model for colon adenocarcinoma based on mitotic catastrophe-related genes.
    Liu Y; Zhao Y; Zhang S; Rong S; He S; Hua L; Wang X; Chen H
    Sci Rep; 2024 Jan; 14(1):1655. PubMed ID: 38238555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).
    Wang L; Cao Y; Guo W; Xu J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):15-24. PubMed ID: 36173462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of Potential Roles of m5C-Related Regulators in Colon Adenocarcinoma Prognosis.
    Huang Y; Huang C; Jiang X; Yan Y; Zhuang K; Liu F; Li P; Wen Y
    Front Genet; 2022; 13():816173. PubMed ID: 35281843
    [No Abstract]   [Full Text] [Related]  

  • 15. Elevated of NDUFA4L2 expression in colon adenocarcinoma is correlated with an unfavorable prognosis and increased immune cell infiltration.
    Mei Q; Chen P; Lv Y; Zheng L; Liu D; Zhang M; Liu W; Li P
    Heliyon; 2024 Feb; 10(3):e25462. PubMed ID: 38352787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
    Gao H; Xing F
    BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a pyroptosis-related lncRNA risk model for predicting prognosis and immune response in colon adenocarcinoma.
    Tan Y; Lu L; Liang X; Chen Y
    World J Surg Oncol; 2022 Apr; 20(1):118. PubMed ID: 35413978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA ALMS1-IT1 is a novel prognostic biomarker and correlated with immune infiltrates in colon adenocarcinoma.
    Lin Y; Li Y; Chen Y; Zhang Z
    Medicine (Baltimore); 2022 Oct; 101(42):e31314. PubMed ID: 36281164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of GIPC2 in colon adenocarcinoma is associated with a favorable prognosis and high levels of immune cell infiltration.
    Kang M; Su Z
    Oncol Rep; 2023 Apr; 49(4):. PubMed ID: 36799193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel prognostic signature composed of 3 cuproptosis-related transcription factors in colon adenocarcinoma.
    Zhou L; Zhang Y; Xu Y; Jiang T; Tang L
    Genes Genomics; 2023 Aug; 45(8):1047-1061. PubMed ID: 37318704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.